PTK2 and neoplasm: Here, we revealed that SRPX2 silencing remarkably decreased p-FAK levels in PTC cells and mouse xenograft tumor tissues (Figure 4), indicating that SRPX2 might function partly in a FAK-dependent pathway to accelerate PTC progression.